LBF20107PG13: Difference between revisions
No edit summary |
No edit summary |
||
| (12 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
{{Metabolite | {{Metabolite | ||
|LipidBank=XPR1751 | |LipidBank=XPR1751 | ||
|LipidMaps=LMFA03010069 | |LipidMaps=LMFA03010069 | ||
|SysName= 9beta,11alpha,15S- | |SysName=(9beta,11alpha,15S) -Trihydroxy-prost-trans-13-en-1-oic acid | ||
|Common Name=&&Prostaglandin | |Common Name=&&Prostaglandin F_1 beta&&(9beta,11alpha,15S) -Trihydroxy-prost-13(E)-en-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=Prostaglandin F1 beta increase respiratory rate after application intravenously.[[Reference:Brookes_LG:Marshall_RC:,J. Pharm. Pharmacol.,1974,26 Suppl,80|{{RelationTable/GetFirstAuthor|Reference:Brookes_LG:Marshall_RC:,J. Pharm. Pharmacol.,1974,26 Suppl,80}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 08:10, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1751 |
| LipidMaps | LMFA03010069 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20107PG13 |
| Prostaglandin F1β | |
|---|---|
| |
| Structural Information | |
| (9β,11α,15S) -Trihydroxy-prost-trans-13-en-1-oic acid | |
| |
| Formula | C20H36O5 |
| Exact Mass | 356.256274262 |
| Average Mass | 356.49684 |
| SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](C[C@H]1O)O)CC |
| Physicochemical Information | |
| Prostaglandin F1 beta increase respiratory rate after application intravenously. Brookes_LG et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
